Mem

Quick links to important sections

Mem

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mem

This section defines the identity and classification of the medicine Mem, which contains the active substance Methylergometrine, while adhering strictly to non-clinical information boundaries.

Property Description
Active ingredient Methylergometrine (Methylergonovine)
Form Oral Tablets, Solution for Injection
Pharmacological Class Uterotonic, Oxytocic Agent
Origin Semisynthetic Ergot Alkaloid Derivative

What is Mem and its Active Ingredient, Methylergometrine?

Mem is a trade name for a single-ingredient prescription medicine that contains the active substance Methylergometrine, also officially known by its International Nonproprietary Name (INN) Methylergonovine. This compound is classified as a semisynthetic compound, meaning its molecular structure is chemically derived from the naturally occurring ergot alkaloids. The medicine is commonly prepared in two main physical forms for medical use: as a sterile solution for injection (an injectable formulation, for parenteral administration) and as standard oral tablets (an oral preparation). This dual preparation profile is a distinctive feature often noted in clinical practice, allowing healthcare providers to select the most appropriate administration route based on the urgency and setting.

What Pharmacological Class Does Mem Belong To?

Mem belongs unequivocally to the pharmacological class of Uterotonics and Oxytocic agents, specifically categorized as an ergot alkaloid derivative. Methylergometrine is recognized as an Essential Medicine, confirming its established global importance as a Uterotonic for managing severe bleeding. Its role as a second-line or alternative agent is clinically recognized when other primary uterotonics are unavailable or contraindicated, underscoring its continued relevance.

What is the General Purpose of This Uterotonic Agent?

The general purpose of this uterotonic agent is to induce and maintain powerful, sustained uterine contractions, coupled with an effect that causes localized vessel narrowing. This mechanism relies on the active ingredient acting directly on the myometrium (uterine muscle) to increase both the tone and amplitude of its rhythmic contractions. The primary benefit of this controlled and forceful myometrial stimulation is the effective compression of blood vessels within the uterus. This action is pharmacologically supported as a critical measure required to manage or prevent the excessive bleeding associated with certain obstetric conditions, particularly in the context of uterine atony.

Regulatory References

  1. Methylergometrine on EML

What side effects are possible with Mem?

The possible adverse reactions and overall safety profile of Mem (containing Memantine) are comprehensively documented in official regulatory labeling for the management of moderate to severe Alzheimer’s dementia. The presentation of adverse reactions is based on standard regulatory classifications, such as those used by the FDA and EMA.

Frequency-Classified Adverse Reactions

The safety profile systematically lists side effects by their documented frequency:

  • Common Reactions: Dizziness, headache, confusion, constipation, hypertension, somnolence, vomiting, and hallucination (observed mainly in severe Alzheimer’s disease) are listed among the most frequently observed events in clinical trials.
  • Uncommon Reactions: These events include abnormal gait, cardiac failure, and venous thrombosis/thromboembolism.
  • Frequency Not Known: Rare, clinically important events identified primarily through post-marketing surveillance, such as acute renal failure, pancreatitis, and suicidal ideation, cannot be reliably estimated for frequency.

Safety Constraints and Special Population Notes

The regulatory profile identifies specific systemic and situational safety constraints:

  • System-Organ Classes: Adverse effects are documented across various systems, notably Nervous System Disorders (e.g., seizures, somnolence) and Gastrointestinal Disorders.
  • Safety Restrictions: Caution is advised regarding co-administration with other NMDA antagonists (like amantadine), as this is associated with a risk of pharmacotoxic psychosis. Additionally, conditions that cause urinary alkalization (high urine pH) may reduce the elimination of the active substance, potentially increasing systemic exposure.
  • Organ Function: Official labeling recommends caution in patients with severe hepatic impairment and in those with renal impairment, where altered clearance of the drug may occur. The medication is not recommended for the pediatric population due to a lack of data.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Memantine overdose documents a range of Central Nervous System (CNS) manifestations and severe outcomes. Documented presentations may include agitation, confusion, hallucination, dizziness, somnolence (sleepiness), and vomiting. More severe manifestations, detailed in regulatory summaries, can involve seizures, psychosis, loss of consciousness, and coma, along with cardiovascular effects such as bradycardia or hypertension.

When to Seek Immediate Medical Help: Government regulatory authorities mandate that immediate emergency services (911) must be contacted if an overdose results in severe clinical signs, specifically when the individual has trouble breathing, cannot be awakened, collapsed, or experienced a seizure. Regulators further state that a poison control center or emergency room should be contacted at once for any suspected overdose event.

Management and Specific Considerations: Because no specific antidote is known, regulatory guidance recommends that general supportive measures must be utilized. Clinical management involves meticulous monitoring of vital signs, blood gases, and serum electrolytes. A specific regulatory note highlights that conditions causing alkaline urine (e.g., due to diet or concurrent drugs) may decrease the urinary elimination of the drug, a factor that could increase systemic exposure and the risk of adverse effects.

Therapeutic Uses of Mem

Quick Facts: What Mem is used for

  • Primary Use: Management of moderate to severe dementia of the Alzheimer’s type.
  • Therapeutic Goal: May support improved cognitive function and overall quality of life.
  • Combination Use: Often used alongside cholinesterase inhibitors in treatment regimens.

Mem is a medication indicated for the management of moderate to severe dementia associated with Alzheimer's disease. The therapeutic goal of this treatment is to help stabilize function in individuals experiencing this condition. By working in the brain, it may support improvements in cognitive domains such as memory and attention, which are often affected by the progression of the disease.

This treatment may also assist in the overall management of daily functional activities and could potentially support an improved quality of life for the patient. A healthcare professional may initiate this medication as monotherapy or in combination with other approved treatments, such as cholinesterase inhibitors, to help achieve maximum symptom control. This application is recognized for the treatment of moderate to severe Alzheimer's dementia. Discussing the full scope of potential benefits and risks with a qualified provider is recommended to determine its suitability for an individual's specific circumstances.

Eligibility and Restrictions for Use

The official regulatory documents define the eligible population for Memantine (Mem), restricting its use based on hypersensitivity, age, and patient-specific physiological status.

Eligibility Status Population/Condition
Contraindicated Patients with a known hypersensitivity (allergy) to the active substance, memantine hydrochloride, or any ingredients in the formulation.
Approved Population Adults with moderate to severe dementia of the Alzheimer’s type. Efficacy and safety data are well-established in the Older Adult population.
Use Not Recommended Children and adolescents under 18 years due to insufficient data on safety and effectiveness. Also not recommended for patients with severe hepatic impairment due to lack of available data.

Use is restricted and requires specific management in other populations:

  • Severe Renal Impairment requires that the maximum daily dosage be reduced, as outlined in prescribing information.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if the potential benefit outweighs the potential risk to the fetus, as there are limited studies. Breastfeeding is generally not recommended.
  • Special Caution is advised for patients with a history of epilepsy or for those with conditions that significantly raise urine pH, which can affect how the drug is eliminated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Methylergometrine's interaction profile is defined by official regulatory documents through two primary categories of constraints: pharmacokinetic and pharmacodynamic.


Contraindicated Combinations

The most significant interaction involves a pharmacokinetic constraint related to the CYP 3A4 enzyme system, which metabolizes the drug. Strong inhibitors of this enzyme, such as certain Macrolide Antibiotics (e.g., Clarithromycin) and HIV Protease Inhibitors (e.g., Ritonavir), are formally contraindicated. Co-administration with these inhibitors significantly increases methylergometrine plasma concentrations, raising the risk for serious adverse events like vasospasm.

A high-risk pharmacodynamic interaction is also documented: co-administration with other vasoconstricting agents, including Serotonin-receptor Agonists (Triptans) and other Ergot Alkaloids, is contraindicated due to the potential for additive effects leading to vasospasm.


Other Documented Interaction Constraints

Caution is required with CYP 3A4 inducers (e.g., Rifampicin), which may decrease drug exposure and potentially reduce its pharmacological action. Pharmacodynamic antagonism is documented with Antianginal Drugs (e.g., Glyceryl Trinitrate), whose therapeutic effect may be reduced.

The regulatory profile notes an interaction with Grapefruit or Grapefruit Juice, which may increase drug levels because it functions as a less potent CYP 3A4 inhibitor. Furthermore, interaction risk is officially noted as requiring caution in patients with impaired hepatic or renal function due to potential decreased drug clearance.

Mechanism of Action

How Mem Works: Modulation of Glutamatergic Activity

Mem functions as a non-competitive, moderate-affinity antagonist of the N -methyl -D -aspartate (NMDA) receptor, a specific ion channel in the central nervous system. Its mechanism involves physically blocking this channel when it is persistently and excessively stimulated by the excitatory neurotransmitter glutamate. This action modulates pathological, overactive signaling while maintaining the physiological, transient nerve impulses necessary for synaptic transmission.


Modulating Neuronal Ca^2+ Ion Homeostasis

The core cascade resulting from this blockage is the modulation of calcium ion ( Ca^2+) flow into the postsynaptic nerve cell. By preventing the sustained and excessive influx of Ca^2+ through the overstimulated NMDA channel, the drug interferes with the excitotoxic process. This action contributes to the maintenance of neuronal functional integrity.

Dosage and Administration Information

How to Use Mem: Official Administration Guidelines

Mem, which contains the active substance methylergometrine, is used according to a defined, two-phase regimen that relies on both parenteral (injection) and oral administration routes. The overall use is strictly confined to a structured, short-term course of treatment limited to the immediate postpartum period.


Administration Pathways and Dosing

The standard adult protocol initiates with the parenteral form. The initial dose is 0.2 mg administered intramuscularly (IM), which is the generally preferred injection route. This IM dose may be repeated every 2 to 4 hours as required, but the total parenteral administration is typically limited to five doses. Should the intravenous (IV) route be necessary, the 0.2 mg solution must be administered slowly over no less than 60 seconds; adherence to this strict rate requirement is mandatory, and the injection solution must be visually inspected before use.

Maintenance and Duration

Following the initial stabilization, treatment transitions to the oral form. The standard oral maintenance dose is 0.2 mg, typically administered three or four times daily (every 6 to 8 hours). The oral tablet may be taken with or without food. The entire duration of therapy—from the first injection to the final oral tablet—is generally restricted to a maximum of seven days postpartum, confirming its use as an acute, time-bound intervention. Safety and effectiveness have not been established in the pediatric population (under 18 years of age).

Recent Clinical Evidence

Mem: Recent Clinical Evidence

Evidence for Use in Moderate to Severe Alzheimer’s Dementia

The evidence base for Mem is primarily characterized by Randomized Controlled Trials (RCTs) and subsequent meta-analyses that explored methods of measuring changes in symptoms of moderate to severe dementia of the Alzheimer’s type. Researchers monitored changes in cognitive function, functional capacity (daily activities), and overall clinical condition. Trials typically compared the research group to a placebo over defined time intervals, usually six to seven months. Regulatory reviews have described patterns observed in these studied outcomes when comparing groups. Study results reflect the specific trial conditions, and research does not determine whether an individual will respond similarly.


Comparison Studies, Follow-up, and Specific Patient Groups

Research explored the use of Mem in different treatment settings, examining outcomes reflecting daily functioning. Some studies evaluated Mem as a single treatment (monotherapy), while others focused on its use in combination therapy with other approved drug classes. These comparison studies examined whether short-term changes were associated with Mem’s use alongside another medicine, versus when it was used alone.

The core clinical research was evaluated in defined, short-term observation periods, typically 24 to 28 weeks of controlled follow-up. Long-term effects are not fully established, and long-term outcomes are not well characterized by the core controlled research. The majority of the evidence examined patient groups categorized as having moderate to severe dementia. Evidence is limited for patients diagnosed with mild Alzheimer's dementia; studies focusing on this group have findings that were mixed or data remain insufficient.


Evidence Gaps and Areas of Uncertainty

Findings describe group patterns, not personal outcomes, and evidence highlights what is known and what is still uncertain. One key limitation is that the outcomes measured in the studies were often described as small by researchers. Furthermore, long-term effects are not fully established, and research has not consistently documented changes in the population with mild Alzheimer's disease.

Frequently Asked Questions (FAQ)

Common questions about Mem (FAQ)


Q: What is the main purpose of Mem and what is it approved to treat?

A: According to official product information, Mem is approved for the prevention and control of postpartum hemorrhage, which is excessive bleeding after childbirth. Its primary role is in the routine management of conditions like uterine atony (a tired, weak uterus) and subinvolution of the uterus after delivery.


Q: How quickly can a person expect to notice the effects of Mem?

A: The onset of effect is highly dependent on the way the medicine is administered. Regulatory information indicates that the effect is immediate when given by intravenous (IV) injection. The onset is reported to be within 2 to 5 minutes after intramuscular (IM) injection and takes 5 to 10 minutes after taking the oral tablet form.


Q: Are there any common lifestyle factors (like diet or exercise) that affect how Mem works?

A: Official guidance indicates that grapefruit or grapefruit juice is typically restricted during treatment, as it may increase the level of the drug in the body. Information regarding the impact of exercise or other broad lifestyle factors is not specified in regulatory labeling.


Q: What are the most commonly reported side effects people experience with Mem?

A: The most common adverse reactions reported in official labeling are hypertension (high blood pressure), headache, and abdominal pain (caused by uterine contractions).


Q: How can I tell the difference between a minor side effect of Mem and a serious one?

A: The label lists severe reactions such as seizure, stroke (cerebrovascular accident), chest pain (myocardial infarction), trouble breathing, and sudden severe headache, which are conditions generally understood to warrant immediate attention from a medical professional.


Q: Is it possible for a side effect of Mem to appear months after starting treatment?

A: Based on official guidelines, the entire course of treatment with Mem is generally limited to a maximum of seven days postpartum. Because of this short, time-bound use, the approved therapeutic context does not involve long-term side effects that appear many months later.


Q: Are there any general safety classifications or pregnancy risk categories for Mem?

A: The drug is generally contraindicated during pregnancy due to its potent effect on causing uterine contractions. Historically, before current classifications, the drug was often categorized based on this risk. Its use is strictly reserved for after the delivery of the baby and placenta.


Q: What are the potential interactions between Mem and common over-the-counter pain relievers (like ibuprofen)?

A: Regulatory documents advise caution when Mem is used with other medications that cause vasoconstriction (narrowing of blood vessels). The official label also warns against co-administration with strong and moderate CYP 3A4 inhibitors, which include certain types of antibiotics and antifungal medicines.


Q: Does Mem interact with vitamins or common dietary supplements (e.g., St. John's Wort)?

A: The label advises caution with substances that inhibit the CYP3A4 enzyme, a system in the liver that processes the drug. In addition to certain medicines, this warning explicitly includes consuming grapefruit juice. Official guidance recommends that patients discuss all supplements and foods, including grapefruit, with their prescribing provider.


Q: Is there a list of ingredients in Mem that patients should be aware of for allergies?

A: Yes, official product information lists the active substance as methylergonovine maleate. The oral tablets also contain various inactive ingredients, such as lactose, sucrose, and certain dyes, which are listed on the label, and patients are typically advised to check these for known allergies.


Q: Is there a risk of dependence or withdrawal symptoms associated with Mem?

A: Regulatory documents explicitly state that the drug has not been associated with drug abuse or dependence. This includes no known risk of either physical or psychological dependence.


Q: Have studies examined the use of Mem in patients with long-term kidney or liver conditions?

A: Official precautions advise that caution should be exercised when the medication is administered to patients who have impaired hepatic or renal function. This is because the body primarily clears the drug through liver metabolism and kidney excretion.


Q: How does the mechanism of action described for Mem relate to the symptoms it is used to manage?

A: The purpose of the drug is achieved because it acts directly on the smooth muscle of the uterus. This action causes rapid and sustained contractions, which helps the uterus return to normal size (subinvolution) and is essential for reducing blood loss (hemorrhage) after delivery.


Q: Can Mem affect a person's ability to operate machinery or drive?

A: Because some potential side effects include dizziness, headache, and confusion, the medication may impair a person's ability to safely drive or operate heavy machinery. Patients are generally advised to be aware of how the medicine affects them before engaging in such activities.


Q: Does Mem affect or interact with birth control pills or other hormonal medications?

A: The label primarily focuses on interactions with vasoconstrictors and CYP3A4 inhibitors. While hormonal contraceptives are not specifically listed, all prescription and non-prescription drugs are typically reviewed with the healthcare team to check for potential risks.


Q: What are the known contraindications for Mem, meaning who absolutely cannot use it?

A: The drug is contraindicated (should not be used) in patients who have hypertension (high blood pressure) or toxemia (a blood pressure condition related to pregnancy). It is also contraindicated during pregnancy and for anyone with a known hypersensitivity or allergy to the drug.


Q: Are there different forms of Mem (e.g., tablet, liquid, extended-release) that have different instructions?

A: Yes, official product information indicates the medication is supplied as tablets for oral use and as an injection solution for intramuscular (IM) or intravenous (IV) administration. Each form has its own specific instructions for use.


Q: What information is available about the effect of Mem on long-term heart health?

A: The label carries warnings about the potential for serious short-term cardiac events. These include adverse reactions such as acute myocardial infarction (heart attack) and ventricular fibrillation, particularly in individuals who may have pre-existing risk factors for heart conditions.


Q: Does Mem interact with common substances like caffeine or nicotine?

A: Regulatory precautions list smoking as a risk factor that may increase the chance of serious side effects, likely due to the vasoconstrictive effects of nicotine. Caffeine is not specifically mentioned, but the medication can interact with substances that narrow blood vessels.


Q: What are the symptoms of an overdose of Mem as described in official documents?

A: Symptoms reported in cases of acute overdose may include severe reactions like nausea, vomiting, abdominal pain, and numbness/tingling of the extremities. A characteristic sign is a sudden rise in blood pressure, which may then be followed by dangerously low blood pressure and respiratory issues in the most severe cases.


Q: Is it normal to feel a change in energy levels when first starting Mem?

A: While the official documentation does not specifically list 'energy level changes' as a side effect, the reported adverse reactions could affect general well-being. These reactions include dizziness, headache, and changes in blood pressure (hypotension or hypertension).


Q: What are the general guidelines for managing common but non-serious side effects of Mem?

A: The regulatory label notes that common side effects, such as abdominal pain, nausea, and vomiting, can occur. Regulatory guidance notes that patients are generally advised to discuss all side effects with their healthcare provider for evaluation.


Q: Can a person take Mem if they have a history of seizures or mental health conditions?

A: Caution is advised for patients with a history of certain neurological issues, as the drug has been associated with rare but serious adverse events. These reactions include seizures, confusion, and hallucinations.


Q: Can Mem cause drowsiness or fatigue, and if so, how long does this generally last?

A: Side effects of the medication include reports of dizziness and lightheadedness, which can be associated with feelings of drowsiness or fatigue. Official regulatory text does not specify how long these effects typically last.


Q: Does Mem carry a specific regulatory warning about potential serious risks?

A: Yes, the official label includes warnings regarding the potential for hypertensive and cerebrovascular accidents (strokes). These risks are emphasized, especially when the injection form of the medication is administered too rapidly via the intravenous route.


Q: Are there any conditions that can be worsened by taking Mem?

A: Official precautions state that the drug should be administered with caution, as certain existing conditions may be worsened. These conditions include sepsis (a serious infection), obliterative vascular disease (which involves blocked arteries), and pre-existing coronary artery disease.


Q: How does Mem affect the nervous system or mental state as described in its regulatory information?

A: Serious adverse reactions reported in official documents indicate a potential effect on the central nervous system. These include rare but serious events such as seizures, cerebrovascular accidents (strokes), and temporary changes in mental state like confusion and hallucinations.


Q: Is it true that Mem is primarily used for its main condition, or is it approved for multiple uses?

A: Mem is approved primarily for its main purpose after the delivery of the placenta. This use is for the routine management of uterine atony (lack of uterine muscle tone), hemorrhage (bleeding), and subinvolution (failure of the uterus to return to its normal size).


Q: What is the half-life of Mem, and what does this mean for how often it is taken?

A: Pharmacokinetic data indicates that the medication has a mean elimination half-life of approximately 3.39 hours. The half-life describes the time it takes for the concentration of the drug in the body to be reduced by half.


Q: Are there any specific organs that Mem is known to affect more than others?

A: Regulatory precautions advise exercising caution related to several key organ systems. These include the liver and kidneys (due to how the body clears the drug) and the heart and blood vessels (due to its vasoconstrictive effects).


Q: Does Mem interact with other prescription medications frequently used for heart conditions or diabetes?

A: Official labeling states that Mem is generally contraindicated or requires caution when used with many medications prescribed for high blood pressure (hypertension). Additionally, caution is advised in patients with pre-existing conditions like diabetes or high cholesterol due to increased risk of adverse events.


Q: How might the administration route (injection vs. oral) affect the body’s response to Mem?

A: The route of administration directly affects the time it takes for the drug to begin working. Regulatory information reports that the onset is fastest with intravenous injection and slowest with the oral tablet form.


Q: What is the general eligibility criteria for people who may be prescribed Mem?

A: The medicine is used in the immediate postpartum period, but official documents state it is contraindicated in patients with hypertension, toxemia (a blood pressure condition related to pregnancy), or known hypersensitivity to the drug.

How should Mem be stored and disposed of?

How to Store and Dispose of Memantine

Memantine (Mem) must be stored and handled according to official regulatory requirements to maintain its stability. The product should be kept in the original, tightly closed container and stored at controlled room temperature (e.g., 20 C to 25 C).


Required Storage Conditions

  • Temperature: Store away from excessive heat; do not store the oral solution above 30 C.
  • Protection: Keep from freezing, light, and moisture.
  • Child Safety: Store out of the sight and reach of children.
  • Stability: The Memantine oral solution must be used within 12 weeks (or 3 months) after first opening.

Disposal

Discard unused or expired product in accordance with local regulations and pharmacy guidance. The medication must not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mem found in:

A-Z Index: